We are excited to announce that Tubulis has dosed the first patient in their Phase I/IIa trial for TUB-040, an antibody-drug conjugate (ADC) targeting NaPi2b, a highly overexpressed antigen in ovarian and lung adenocarcinoma.
This innovative treatment, developed using Tubulis’ proprietary P5 technology, shows great promise for patients with platinum-resistant high-grade ovarian cancer and relapsed/refractory adenocarcinoma non-small cell lung cancer.
Tubulis’ P5 technology is an innovative chemistry for cysteine-selective conjugation enabling the creation of antibody-drug conjugates (ADCs) with exceptional linker stability and superior biophysical properties. Preclinical data have shown that this technology allows for efficient delivery of the therapeutic payload directly to the tumor while minimizing off-target toxicities.
The clinical trial will enroll up to 140 patients across the US, UK, Spain, Belgium and Germany, aiming to investigate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040 as a monotherapy.
Congratulations to the entire Tubulis team on this significant achievement! We are proud to support your mission to revolutionize cancer treatment with advanced ADCs.
More information in the press release under the following link
More about Tubulis
